Trial Profile
A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Figitumumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 03 Jul 2012 This trial is recruiting in France and has been completed in Belgium.
- 03 Mar 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.